May 2, 2013

Drug makers Boehringer Ingelheim and Eli Lilly have started a campaign designed to educate healthcare professionals about the role a type of protein plays in maintaining blood-sugar balance.

April 5, 2013

Boehringer-Ingelheim helped sponsor Team Walgreens/Team Tori to a tune greater than $1,000 for colon cancer research at the 2013 St. Louis Undy 5000, a family-friendly 5K run/walk created by the Colon Cancer Alliance. BI is a regular sponsor of Undy 5000 events under its Dulcolax brand.

March 25, 2013

Boehringer Ingelheim and Eli Lilly are seeking regulatory approval for an experimental drug to treat Type 2 diabetes, the companies said.

January 30, 2013

A panel of Food and Drug Administration experts has recommended approval for an experimental drug made by Boehringer Ingelheim for chronic obstructive pulmonary disease, the drug maker said.

January 17, 2013

Boehringer Ingelheim Pharmaceuticals has enrolled the first patients in its late-stage trial of a treatment for hepatitis C, the drug maker said Thursday.

November 29, 2012

Boehringer Ingelheim recently expanded its popular laxative brand with Dulcolax Laxative Tablets for Women, specifically formulated with a “comfort-coating” to protect a woman’s stomach. 


November 9, 2012

Drug maker Boehringer Ingelheim has created a website designed for patients with hepatitis C and advocates, the company said Friday.

September 20, 2012

Procter & Gamble this week will begin shipping a wildberry-flavored Prilosec OTC.

September 19, 2012

The Undy 5000 5K Run/Walk, presented by Dulcolax, returned to Philadelphia for the fifth consecutive year to help raise funds for colon cancer research.

September 18, 2012

Boehringer Ingelheim Pharmaceuticals has launched a drug for treating chronic obstructive pulmonary disease, the company said Tuesday.

September 14, 2012

Drug makers Boehringer Ingelheim and Eli Lilly have created a new online educational program for people with Type 2 diabetes.

July 31, 2012

The 2012 Jersey Shore Undy 5000 raised more than $80,000 for local and national colon cancer screening, awareness and support programs, Boehringer-Ingelheim — which sponsored the event under its Dulcolax brand — announced Saturday.

May 22, 2012

Boehringer Ingelheim last week announced the launch of Dulcolax Laxative Tablets for Women — tablets that are "comfort-coated" to protect a woman's stomach so the active ingredient, bisacodyl, is released only in the large intestine — to correspond with National Women's Health Week.

March 29, 2012

A nonprofit organization focused on chronic obstructive pulmonary disease will take over a COPD awareness campaign from the drug company that started it.

March 12, 2012

One of pharmacy's top awards is getting some support from a German drug maker. Boehringer Ingelheim announced that it became a premier supporter of the American Pharmacists Association's Bowl of Hygeia Award.

March 8, 2012

The market for drugs to treat diabetes — especially Type 2 diabetes — has shown quite a bit of activity lately.

March 7, 2012

A new drug for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim is available in pharmacies, the companies said Wednesday.

February 8, 2012

An antiplatelet medication created by Boehringer Ingelheim is not affected when co-administered with a proton-pump inhibitor, according to results of a drug interaction study.

January 31, 2012

The Food and Drug Administration has approved a new treatment for Type 2 diabetes made by Eli Lilly and Boehringer Ingelheim, the drug makers said.

December 8, 2011

A drug currently under clinical development for Type 2 diabetes produced "meaningful" reductions in blood sugar, according to results of a late-stage clinical study.

November 15, 2011

German drug maker Boehringer Ingelheim Pharmaceuticals invested more than $350 million in its U.S. operations this year, the company said Tuesday.

November 8, 2011

Eli Lilly and Amylin Pharmaceuticals are ending their diabetes-drug alliance, the two companies said Tuesday.

October 10, 2011

The Food and Drug Administration has approved a new product for chronic obstructive pulmonary disease made by Boehringer Ingelheim Pharmaceuticals, the drug maker said.

October 6, 2011

Gilead Sciences has signed an agreement with Boehringer Ingelheim to gain exclusive worldwide rights to research, develop and commercialize BI's novel anti-retroviral compounds.